Welcome Note: Dr. Ravinder Yadav from Medical Learning Hub welcomed the esteemed speaker, Dr. Durgesh Makwana, Dr. Devashish Desai along with the participants.
Session 1 : Epidemiology of Antibiotic Resistance in India and its challenges by :Dr. Durgesh Makwana, Senior Consultant in the Medical and Surgical ICU at Ruby Hall Clinic, Pune, the session covered :
What is AMR? Microbes resist drugs, causing treatment failures and higher mortality.
Global Impact: 1.27M deaths (2019); projected 39M by 2050.
India’s Crisis:
High resistance in Klebsiella (>40% carbapenem-resistant), E. coli (>60% ESBL).
MRSA (30-40%), rising colistin resistance.
15-30% ICU infections involve resistant pathogens.
Weak regulations, poor diagnostics, lack of awareness.
Antibiotic misuse in livestock & agriculture.
ICMR Surveillance: Tracks resistance nationwide.
National Action Plan: Promotes stewardship, infection control.
Public Awareness: Red Line Campaign, stricter prescription rules.
One Health Approach: Links human, animal, and environmental health.
Session 2 : Treatment Approaches of Antibiotic Resistance by Dr. Devashish Desai, Consultant (Infectious Diseases), Ruby Hall Clinic, Pune, the session covered :
XDR Typhoid: Resistant to ciprofloxacin/ceftriaxone; needs meropenem.
MDR E. coli UTI: Susceptible only to piperacillin-tazobactam.
Pan-Resistant Klebsiella: Only tigecycline worked (NDM/OXA-48 genes detected).
XDR Acinetobacter: Ventilator pneumonia; no options except tigecycline.
β-Lactamases: Class A (ESBLs/KPC), Class B (NDM/VIM), Class D (OXA-48).
Avibactam inhibits Class A/C/D but not NDM (Class B).
Colistin resistance (mcr-1 gene not detected here but rising globally).
XDR typhoid, carbapenem-resistant Pseudomonas, VRE.
Last-resort antibiotics (e.g., tigecycline, colistin) are often the only options.
Combination therapy may be needed for synergistic effects.
Prevention: Antimicrobial stewardship, infection control (e.g., in ICUs), and vaccination (e.g., typhoid).
Q&A Session: Participants actively engaged in a Q&A session moderated by Dr. Ravinder, where Dr. Durgesh Makwana and Dr. Devashish Desai, addressed queries and shared expert insights.
Closing Remarks: Dr. Ravinder concluded the session with a vote of thanks, appreciating the speaker and participants for their valuable contributions.
We wish you a great learning experience!
Tittle: Antibiotic Resistance Patterns in India: Insights, Challenges, and Pathways to Mitigation
- Session 1 : Epidemiology of Antibiotic Resistance in India and its challenges : Dr. Durgesh Makwana, Senior Consultant in the Medical and Surgical ICU at Ruby Hall Clinic, Pune. (20 mins)
- Session 2 : Treatment Approaches of Antibiotic Resistance: Dr Devashish Desai, Consultant (Infectious Diseases), Ruby Hall Clinic, Pune. (20 mins)
- Q&A Session: (10 min)
- Vote of Thanks : (5 mins)
- Consultant
- Family medicine
- Pediatricians
- ENTs
- GPs
- ID specialist
